Sarcomatoid mesothelioma
diseaseOn this page
Also known as malignant fibrous mesothelioma (morphologic abnormality)sarcomatoid mesothelioma (morphologic abnormality)
Summary
Sarcomatoid mesothelioma (MONDO:0006407) is a disease and 3 clinical trials. Top therapeutic interventions include cisplatin, cediranib maleate, and tivantinib. A subtype of malignant mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | sarcomatoid mesothelioma |
| Mondo ID | MONDO:0006407 |
| EFO | EFO:1000521 |
| DOID | DOID:4488 |
| NCIT | C45655 |
| UMLS | C0334513 |
| MedGen | 137774 |
| GARD | 0024401 |
| Is cancer (heuristic) | no |
Also known as: malignant fibrous mesothelioma (morphologic abnormality) · sarcomatoid mesothelioma · sarcomatoid mesothelioma (morphologic abnormality)
Disease family
This is a subtype of malignant mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mesothelioma › sarcomatoid mesothelioma
Related subtypes (10): ovarian malignant mesothelioma, malignant pericardial mesothelioma, malignant pleural mesothelioma, malignant peritoneal mesothelioma, malignant epithelioid mesothelioma, malignant biphasic mesothelioma, localized pleural mesothelioma, diffused pleural mesothelioma, pleural mesothelioma in situ, mesothelioma of the tunica vaginalis
Subtypes (2): lymphohistiocytoid mesothelioma, pleural sarcomatoid mesothelioma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01064648 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma |
| NCT01861301 | PHASE2 | TERMINATED | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma |
| NCT02399371 | PHASE2 | COMPLETED | Pembrolizumab in Treating Patients With Malignant Mesothelioma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| TIVANTINIB | 3 | 1 |
| CHEMBL4475379 | 0 | 1 |
| CHEMBL4785734 | 0 | 1 |
Related Atlas pages
- Drugs: Cisplatin, Cediranib, Tivantinib